NASDAQ:SANA
Sana Biotechnology, Inc.
Sana Biotechnology, Inc. reported net income of −$244.2M in fiscal 2025. Free cash flow was −$144.8M, and the diluted share count rose 9.7%.Summary generated from Sana Biotechnology, Inc.'s SEC filings. Latest annual report filed Mar 3, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−118.7%
Debt / equityn/a
Free cash flow−$144.8M
FCF marginn/a
Share count change+9.7%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −357 | −273 | −293 | −273 | −250 |
| Net income | −356 | −269 | −283 | −267 | −244 |
| Free cash flow | −281 | −311 | −274 | −257 | −145 |
Recent filings
- 4Insider transaction report
Oct 6, 2026 - 8-KRegulation FD disclosure
Sep 8, 2026 - 4Insider transaction report
Aug 27, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 10, 2026 - 8-KResults of operations and financial condition
Aug 10, 2026 - 8-KResults of a shareholder vote
Jun 5, 2026 - 8-KOther events
May 15, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 11, 2026